TG Therapeutics, Inc. (TGTX)
54.17
+1.01
(+1.90%)
USD |
NASDAQ |
Oct 23, 16:00
54.35
+0.18
(+0.33%)
After-Hours: 20:00
TG Therapeutics Enterprise Value : 8.494B for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 8.494B |
| October 22, 2026 | 8.340B |
| October 21, 2026 | 8.346B |
| October 20, 2026 | 8.550B |
| October 19, 2026 | 8.361B |
| October 16, 2026 | 8.464B |
| October 15, 2026 | 8.775B |
| October 14, 2026 | 8.525B |
| October 13, 2026 | 8.520B |
| October 12, 2026 | 8.663B |
| October 09, 2026 | 8.678B |
| October 08, 2026 | 8.367B |
| October 07, 2026 | 8.308B |
| October 06, 2026 | 8.191B |
| October 05, 2026 | 8.455B |
| October 02, 2026 | 8.513B |
| October 01, 2026 | 8.410B |
| September 30, 2026 | 8.741B |
| September 29, 2026 | 8.804B |
| September 28, 2026 | 8.804B |
| September 25, 2026 | 8.993B |
| September 24, 2026 | 9.007B |
| September 23, 2026 | 8.775B |
| September 22, 2026 | 9.098B |
| September 21, 2026 | 8.952B |
| Date | Value |
|---|---|
| September 18, 2026 | 8.908B |
| September 17, 2026 | 8.846B |
| September 16, 2026 | 8.752B |
| September 15, 2026 | 8.321B |
| September 14, 2026 | 8.468B |
| September 11, 2026 | 8.452B |
| September 10, 2026 | 8.681B |
| September 09, 2026 | 8.568B |
| September 08, 2026 | 8.735B |
| September 04, 2026 | 8.772B |
| September 03, 2026 | 8.883B |
| September 02, 2026 | 8.912B |
| September 01, 2026 | 8.788B |
| August 31, 2026 | 8.514B |
| August 28, 2026 | 8.458B |
| August 27, 2026 | 8.732B |
| August 26, 2026 | 8.626B |
| August 25, 2026 | 8.686B |
| August 24, 2026 | 8.776B |
| August 21, 2026 | 8.510B |
| August 20, 2026 | 7.942B |
| August 19, 2026 | 8.115B |
| August 18, 2026 | 7.896B |
| August 17, 2026 | 7.746B |
| August 14, 2026 | 7.663B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Krystal Biotech, Inc. | 8.382B |
| Vertex Pharmaceuticals, Inc. | 126.85B |
| SELLAS Life Sciences Group, Inc. | 2.192B |
| Travere Therapeutics, Inc. | 4.844B |
| Alnylam Pharmaceuticals, Inc. | 29.64B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 7.781M |
| Revenue (Quarterly) | 240.34M |
| Total Expenses (Quarterly) | 232.55M |
| EPS Diluted (Quarterly) | 0.0495 |
| Gross Profit Margin (Quarterly) | 82.86% |
| Profit Margin (Quarterly) | 3.24% |
| Earnings Yield | 5.07% |
| Operating Earnings Yield | 1.58% |
| Normalized Earnings Yield | 5.165 |